Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced ...
Newsshooter

Atomos Quarterly Activities/Appendix 4C Cash Flow Report

Atomos has released its Quarterly Activities/Appendix 4C Cash Flow Report. This Report is for the three-month period that ...
Nasdaq

Amaero Releases Appendix 4E and Audited Financial Report and Issues Letter to Shareholders

~ Revenues from Ordinary Activities up 470% and Revenues from Contracts with Customers from Continuing Operations up 722% to A$3.8 Million ~ ~ Annual General Meeting to be Held on Tuesday, November 18 ...

SATO Corporation Interim Report 1 January–30 September 2025: Portfolio investment boosts SATO’s profitable growth

SATO Corporation, Interim Report 28 October 2025 at 9:00 am EET This is a summary of SATO’s interim report for January–September, which has been published in full as an appendix to the release and at ...